Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8450263rdf:typepubmed:Citationlld:pubmed
pubmed-article:8450263lifeskim:mentionsumls-concept:C0035436lld:lifeskim
pubmed-article:8450263lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:8450263lifeskim:mentionsumls-concept:C0039195lld:lifeskim
pubmed-article:8450263lifeskim:mentionsumls-concept:C0442805lld:lifeskim
pubmed-article:8450263lifeskim:mentionsumls-concept:C0301630lld:lifeskim
pubmed-article:8450263lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:8450263lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:8450263lifeskim:mentionsumls-concept:C2003905lld:lifeskim
pubmed-article:8450263lifeskim:mentionsumls-concept:C0221049lld:lifeskim
pubmed-article:8450263pubmed:issue4lld:pubmed
pubmed-article:8450263pubmed:dateCreated1993-4-12lld:pubmed
pubmed-article:8450263pubmed:abstractTextIn a prospective study, patients with acute rheumatic fever (ARF) and active rheumatic heart disease (ARHD) showed a significant increase in CD4+ T cells, CD22+ B cells, and CD4:CD8 cell ratio but a significant decrease in the percentages of CD8+ and CD3+ T lymphocytes compared with patients with quiescent RHD (CRHD) or streptococcal pharyngitis (SP) and normal controls. The proportion of interleukin-2 receptor (IL-2R)+ (CD25+) cells was higher in peripheral blood mononuclear cell cultures (both before and after phytohemagglutinin stimulation) of ARF and ARHD patients than in those of CRHD or SP patients or controls; this finding persisted up to 48 weeks. In ARF patients, the percentage of CD8+ cells returned to within normal range at 48 weeks. Furthermore, the percentage of IL-2R+ cells correlated positively with the percentage of CD4+ but not of CD8+ lymphocytes, suggesting that helper/inducer T cells are in an immunologically activated state and may account for aberrations in the distribution of lymphocyte populations in peripheral blood of ARF and ARHD patients.lld:pubmed
pubmed-article:8450263pubmed:languageenglld:pubmed
pubmed-article:8450263pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8450263pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8450263pubmed:statusMEDLINElld:pubmed
pubmed-article:8450263pubmed:monthAprlld:pubmed
pubmed-article:8450263pubmed:issn0022-1899lld:pubmed
pubmed-article:8450263pubmed:authorpubmed-author:WahiP LPLlld:pubmed
pubmed-article:8450263pubmed:authorpubmed-author:MohanCClld:pubmed
pubmed-article:8450263pubmed:authorpubmed-author:GangulyN KNKlld:pubmed
pubmed-article:8450263pubmed:authorpubmed-author:MorrisKKlld:pubmed
pubmed-article:8450263pubmed:authorpubmed-author:AnandI SISlld:pubmed
pubmed-article:8450263pubmed:issnTypePrintlld:pubmed
pubmed-article:8450263pubmed:volume167lld:pubmed
pubmed-article:8450263pubmed:ownerNLMlld:pubmed
pubmed-article:8450263pubmed:authorsCompleteYlld:pubmed
pubmed-article:8450263pubmed:pagination979-83lld:pubmed
pubmed-article:8450263pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:meshHeadingpubmed-meshheading:8450263-...lld:pubmed
pubmed-article:8450263pubmed:year1993lld:pubmed
pubmed-article:8450263pubmed:articleTitleIncrease in activated T cells and reduction in suppressor/cytotoxic T cells in acute rheumatic fever and active rheumatic heart disease: a longitudinal study.lld:pubmed
pubmed-article:8450263pubmed:affiliationDepartment of Experimental Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.lld:pubmed
pubmed-article:8450263pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8450263pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8450263lld:pubmed